Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 2 of 23
Aug 27, 2026France’s Osivax will lead development of a combination vaccine pairing its influenza A candidate OVX836 with GC Biopharma’s inactivated seasonal flu vaccine, GC FLU. The agreement gives Osivax the components it needs to move from separate injections toward a single product that it believes could broaden protection while avoiding the friction of two shots.
Dr. Priya Nandakumar
Aug 27, 2026Akeso described the Harmoni-GI1 result as clinically meaningful and statistically significant on overall survival, with progression-free survival and objective response rate also met. Strategically, the readout broadens the drug’s tumor-type story at a time when debate over changing progression-free survival magnitudes in lung cancer has sharpened attention on what kind of evidence regulators may ultimately value most.
Daniel Cho
Aug 26, 2026Rasonque was cleared for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval arrived more than half a year before the Prescription Drug User Fee Act deadline after a review that included the FDA’s Commissioner’s National Priority Voucher program.
Sophia Reynolds
Aug 26, 2026The FDA approved Ziihera for newly diagnosed patients with unresectable locally advanced or metastatic gastroesophageal adenocarcinoma with HER2 mutations. For Jazz, the label expansion shifts attention from regulatory risk to launch execution in what Truist projects as the drug’s biggest commercial setting.
Emily Carter
Aug 25, 2026The FDA approval covers intravenously infused nipocalimab, sold as Imaavy, for treating patients age 12 and older with warm autoimmune hemolytic anemia. For J&J, the label expansion adds a first-in-disease position in a rare condition while supporting the company’s broader thesis that Imaavy can become a multibillion-dollar immunology product.
Jonathan Blake
Aug 25, 2026Foundayo is approved in the U.K. for adults with obesity or who are overweight and have at least one weight-related comorbidity, and it is also indicated for type 2 diabetes. Analysts cited by BioSpace said Lilly may be better positioned outside the U.S. because Foundayo is a small-molecule drug, potentially supporting better margins and more pricing flexibility than a peptide rival.
Dr. Priya Nandakumar
Aug 24, 2026TA-ERT could become the first FDA-approved therapy for MPS IIIB if Spruce reaches the regulator on its revised timeline. The latest update matters less as a clinical surprise than as a manufacturing de-risking step for a program whose data were viewed as more settled than its CMC path.
Dr. Priya Nandakumar
Aug 24, 2026Roche’s Genentech unit is taking global rights to HM17321 outside South Korea, while Hanmi completes the ongoing phase 1 study before Genentech assumes later development. Strategically, the deal broadens Roche’s obesity portfolio beyond GLP-1 and GIP programs toward body-composition claims that next-generation obesity developers increasingly want to own.
Michael Torres
Aug 23, 2026Neumora is reorganizing its top team as it approaches a cluster of near-term development events. The timing matters because the company is trying to advance an NLRP3 inhibitor into the clinic for obesity while also generating early data in Alzheimer’s disease and schizophrenia.
Sophia Reynolds
Aug 22, 2026The hold interrupts an early clinical program that had only started in early July and that included healthy male and healthy female participants in separate parts of the study. For investors and peers, the immediate signal is less about a single asset than about how little visibility companies sometimes provide when a first-in-human or early-stage safety review begins.
Sophia Reynolds
Aug 22, 2026Patients treated with Keytruda plus intismeran autogene lived longer without recurrence than patients on Keytruda alone in the Phase 3 INTerpath-001 study. For Merck, the significance is broader than one melanoma readout: it adds a new potential revenue stream as the company prepares for Keytruda’s patent slide starting in 2028.
Michael Torres
Aug 22, 2026The approval covers adults and children age 8 and older with glycogen storage disease type Ia and positions Genglycos as an adjunct to nutritional management that can reduce daily cornstarch intake. For Ultragenyx, the decision is both a product launch and a platform validation point after years of investment in gene therapy.
Dr. Alex MorganMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.